Navigation Links
Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics

PLANTATION, Fla. and MONTREAL, June 2, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI), a full service CMO focused on process development and GMP manufacturing of cell culture derived biopharmaceuticals, and Alethia Biotherapeutics, Inc., a biotechnology company focused on monoclonal antibody development with a very sensitive and highly disease-tissue specific proprietary target discovery platform, announced a collaboration on the development of a mammalian cell line-based IgG monoclonal antibody project that is anticipated to make a significant impact in the treatment of selected cancers. Terms of the agreement were not disclosed.

"AB-16B5 is a humanized IgG2 monoclonal antibody which targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT), and it has shown positive pre-clinical results in representative cancer models derived from various solid tumors," notes Mario Filion, Ph.D., Executive VP and CSO at Alethia Biotherapeutics. "And, we are pleased to select GBI as our development and GMP manufacturing partner for our first product candidate."

"We at GBI would like to echo that comment. We are pleased to partner with Alethia Biotherapeutics on this important project," says SooYoung Lee, PhD and Senior Vice President of Operations at GBI. "In the biologics CMO niche, we were among the first to engineer the concept of 'full integration', which enables us to work with our clients from Proof of Concept through the manufacture of pre-clinical, and clinical trial products. It is a process we termed 'GMPnization'. In other words, we begin with the end in mind. We employ appropriate stringent regulatory and quality systems to supply product candidates during the development cycle from the initial 'production' cell line development all the way through scale up steps leading to the final cGMP compliant manufacturing process and vialing of the final biopharmaceutical product."

About Goodwin Biotechnology, Inc. Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.

About Alethia Biotherapeutics Inc.Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops innovative therapeutic approaches in areas of unmet medical needs. The Company is currently focusing its development efforts on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss, three areas for which there are very few therapeutic alternatives. Alethia capitalizes on its ability to identify and validate disease-specific targets for the development of highly focused antibody-based therapeutics.

For more information, please contact: Goodwin Biotechnology: Dave Cunningham

Director of Business Development

(954) 327-9639;

DCunningham@goodwinbio.comAlethia BiotherapeuticsYves Cornellier

President and CEO

Tel: (514) 858-7666 ext.206

SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
4. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
5. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
6. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
7. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
8. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
9. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
10. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
11. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about the ... had high blood pressure due to loud noises," she said, "so I decided that ... pollution as well as radio waves and microwaves." , The baby BABY MUFF prevents ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell of Peconic ... on Long Island’s east end. During the broadcast, entitled “Eyes: the Window to the ... glaucoma and cataracts, and how a visit with his grandmother to her physician put ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors ... independent living, assisted living and all other retirement options. Support for issues surrounding ... research remains a top priority. , So it’s no surprise that every ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that they are showcasing ... dentists to make complex business decisions by providing the tools and information they need ... survey with 10 procedures customized by zip code. , The Sikka Software Ecosystem ...
Breaking Medicine News(10 mins):